Efficacy of an existing product for the treatment of osteoarthritis (OA) in cats
OpenDescription
A new study is investigating the efficacy of an existing product for the treatment of osteoarthritis (OA) in cats. It is already FDA-approved for the treatment of OA in dogs and horses, however, there is currently limited information on its use in feline patients.
This study investigates the efficacy of the product in felines with osteoarthritis (OA). The study will evaluate improvements in pain and other clinical signs throughout treatment. The investigational product will be administered once every 4 or 7 days until a total of 8 doses are received. If successful, the investigational product could offer a promising treatment option for cats suffering from OA, potentially improving their quality of life and providing veterinarians with a valuable tool in managing this condition.
ELIGIBILITY CRITERIA
- The patient is 6 months or older
- Diagnosed with osteoarthritis in at least 1 joint in which evidence overlaps between radiographic confirmation and orthopedic examination
- Washout period for specific medications may vary and are outlined in the study protocol
- No intra-articular injections within 30 days
- No known sensitivity to polysulfated glycosaminoglycan or its components
- Not pregnant or lactating/not planned to be used for breeding purposes
- Has not participated in a clinical trial within the past 30 days
- No evidence of coagulopathy or prolonged bleeding times
PARTICIPATING HOSPITALS
- Colorado Animal Specialty and Emergency Hospital (CASE), Boulder, CO
- SAGE Veterinary Center – Campbell, Campbell, CA
Interested?
Enroll or request more information below.